ACEIs and ARBs and Their Correlation with COVID-19: A Review

References

• Dhama K, Patel SK, Pathak M, et al. An update on SARS-COV-2/COVID-19 with particular reference on its clinical pathology, pathogenesis, immunopathology and mitigation strategies–a review. Travel Med Infect Dis. 2020.
   Web of Science ®Google Scholar
• Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020;14(1):64–68. doi:10.5582/bst.2020.0103032037389
   PubMed Web of Science ®Google Scholar
• Organization WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance; 1 28, 2020.
   Google Scholar
• Available from: https://covid19.who.int/?gclid=CjwKCAjwsan5BRAOEiwALzomX9QXX9YInbXvWdchwpisFFagRGptECzLWx6ZeUZ_vEqUsxwbfWzkhoC5F4QAvD_BwE. Accessed 811, 2020.
   Google Scholar
• Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130–137.29052924
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi:10.1038/s41586-020-2012-732015507
   PubMed Web of Science ®Google Scholar
• Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–73. doi:10.5582/bst.2020.0104732074550
   PubMed Web of Science ®Google Scholar
• Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400. doi:10.1016/S1473-3099(20)30141-932113510
   PubMed Web of Science ®Google Scholar
• Available from: Recommendation_Unproven_Therapies_COVID-19.pdf. Accessed 811, 2020.
   Google Scholar
• Akpovwa H. Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity. Cell Biochem Funct. 2016;34(4):191–196. doi:10.1002/cbf.318227001679
   PubMed Web of Science ®Google Scholar
• Lajoie J, Mwangi L, Fowke KR. Preventing HIV infection without targeting the virus: how reducing HIV target cells at the genital tract is a new approach to HIV prevention. AIDS Res Ther. 2017;14(1):46. doi:10.1186/s12981-017-0166-728893304
   PubMed Web of Science ®Google Scholar
• Kumar A, Liang B, Aarthy M, et al. Hydroxychloroquine inhibits zika virus NS2B-NS3 protease. ACS Omega. 2018;3(12):18132–18141. doi:10.1021/acsomega.8b0100230613818
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi:10.1016/j.clim.2020.10839332222466
   PubMed Web of Science ®Google Scholar
• Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2). doi:10.1128/mBio.00221-18.
   PubMed Web of Science ®Google Scholar
• Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020;382(10):929–936. doi:10.1056/NEJMoa200119132004427
   PubMed Web of Science ®Google Scholar
• Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res. 2019;105:93–116.31522710
   PubMed Web of Science ®Google Scholar
• Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. doi:10.1016/j.jaut.2020.10243332113704
   PubMed Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281–292.e6. doi:10.1016/j.cell.2020.02.05832155444
   PubMed Web of Science ®Google Scholar
• Lau YL, Peiris JS. Pathogenesis of severe acute respiratory syndrome. Curr Opin Immunol. 2005;17(4):404–410. doi:10.1016/j.coi.2005.05.00915950449
   PubMed Web of Science ®Google Scholar
• Perico L, Benigni A, Remuzzi G. Should Covid-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade. Nephron. 2020;1–9.
   Web of Science ®Google Scholar
• Crowley SD, Rudemiller NP. Immunologic effects of the renin-angiotensin system. J Am Soc Nephrol. 2017;28(5):1350–1361. doi:10.1681/ASN.201610106628151411
   PubMed Web of Science ®Google Scholar
• Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pöhlmann S. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol. 2014;88(2):1293–1307. doi:10.1128/JVI.02202-1324227843
   PubMed Web of Science ®Google Scholar
• Brojakowska A, Narula J, Shimony R, Bander J. Clinical implications of SARS-Cov2 interaction with renin angiotensin system. J Am Coll Cardiol. 2020;75(24):3085–3095. doi:10.1016/j.jacc.2020.04.02832305401
   PubMed Web of Science ®Google Scholar
• Rossi GP, Sanga V, Barton M. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. Elife. 2020;9:e57278. doi:10.7554/eLife.5727832250244
   PubMed Web of Science ®Google Scholar
• Simões e Silva A, Silveira K, Ferreira A, Teixeira M. ACE2, angiotensin‐(1‐7) and M as receptor axis in inflammation and fibrosis. Br J Pharmacol. 2013;169(3):477–492. doi:10.1111/bph.1215923488800
   PubMed Web of Science ®Google Scholar
• Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–760. doi:10.1080/22221751.2020.174620032228222
   PubMed Web of Science ®Google Scholar
• Li F. Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J Virol. 2015;89(4):1954–1964. doi:10.1128/JVI.02615-1425428871
   PubMed Web of Science ®Google Scholar
• Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Molecular Biol. 2015;1282:1–23.
   PubMedGoogle Scholar
• Wysocki J, Lores E, Ye M, Soler MJ, Batlle D. Kidney and Lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: implications for COVID-19. bioRxiv. 2020.
   Google Scholar
• Guo J, Huang Z, Lin L, Lv J. Coronavirus disease 2019 (COVID‐19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc. 2020;9(7):e016219.32233755
   PubMed Web of Science ®Google Scholar
• Leclézio A, Robinson J, Banerjee I. SARS-CoV-2: ACE inhibitors, disastrous or desirable? J Biomed Sci. 2020;7(1):40–46. doi:10.3126/jbs.v7i1.29852
   Google Scholar
• Maione A, Navaneethan SD, Graziano G, et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant. 2011;26(9):2827–2847. doi:10.1093/ndt/gfq79221372254
   PubMed Web of Science ®Google Scholar
• Barnes M, Heywood AE, Mahimbo A, Rahman B, Newall AT, Macintyre CR. Acute myocardial infarction and influenza: a meta-analysis of case-control studies. Heart. 2015;101(21):1738–1747. doi:10.1136/heartjnl-2015-30769126310262
   PubMed Web of Science ®Google Scholar
• Abuissa H, Jones PG, Marso SP, O’Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 2005;46(5):821–826. doi:10.1016/j.jacc.2005.05.05116139131
   PubMed Web of Science ®Google Scholar
• Arendse LB, Danser AHJ, Poglitsch M, et al. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Pharmacol Rev. 2019;71(4):539–570. doi:10.1124/pr.118.01712931537750
   PubMed Web of Science ®Google Scholar
• Tikellis C, Thomas M. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept. 2012;2012.
   Google Scholar
• Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi:10.1016/S2213-2600(20)30079-532105632
   PubMed Web of Science ®Google Scholar
• Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv. 2020.
   Google Scholar
• Formoso G, Lombardi M. Is drug choice by general practitioners influenced by exposure to specialists? Record-linkage study in Italy. J Health Serv Res Policy. 2016;21(1):24–28. doi:10.1177/135581961559979926254186
   PubMed Web of Science ®Google Scholar
• Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020.
   Google Scholar
• Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci. 2020;134(5):543–545. doi:10.1042/CS2020016332167153
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. doi:10.1016/j.cell.2020.02.05232142651
   PubMed Web of Science ®Google Scholar
• Lewis T. Smoking or vaping may increase the risk of severe coronavirus infection. Sci Am. 2020;17.
   Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. doi:10.1016/S0140-6736(20)30251-832007145
   PubMed Web of Science ®Google Scholar
• Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811. doi:10.1001/jamacardio.2020.101732219356
   PubMed Web of Science ®Google Scholar
• Zou Z, Yan Y, Shu Y, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun. 2014;5(1):1–7. doi:10.1038/ncomms4594
   Web of Science ®Google Scholar
• Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi:10.1016/S2213-2600(20)30116-832171062
   PubMed Web of Science ®Google Scholar
• Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res. 2017;125:21–38. doi:10.1016/j.phrs.2017.06.00528619367
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med. 2005;11(8):875–879. doi:10.1038/nm126716007097
   PubMed Web of Science ®Google Scholar
• Gu H, Xie Z, Li T, et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci Rep. 2016;6:19840. doi:10.1038/srep1984026813885
   PubMed Web of Science ®Google Scholar
• Henery C, Zaizafoun M,Stock E, Ghamande S, Arroliga AC, White HD, editors.Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia Baylor University Medical Center Proceedings. Taylor & Francis; 2018;31(4):419–423.
   Google Scholar
• Rabindranath K, Supershad S, Talreja NDDH, et al. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (Corona Virus Disease 2019). N Z Med J. 2020;133(1512):85–87.
   Web of Science ®Google Scholar
• Battistoni A, Volpe M. Might renin–angiotensin system blockers play a role in the COVID-19 pandemic? Eur Heart J Cardiovasc Pharmacother. 2020;6(4):248–251. doi:10.1093/ehjcvp/pvaa03032286607
   PubMed Web of Science ®Google Scholar
• Aronson JK, Ferner RE. Drugs and the renin-angiotensin system in COVID-19. BMJ. 2020;m1313. doi:10.1136/bmj.m131332241880
   PubMed Web of Science ®Google Scholar